Leigh Baxt, PhD, is a Lead, Drug Development in the MSK Therapeutics Bridge Labs (TxBL) program in the Office of Entrepreneurship & Commercialization. Her responsibilities include leading biologics and small molecule projects from inception to completion and providing expertise on assay development and implementation. She also leads education initiatives for the TxBL team. She joined MSK in September 2025 and most recently served as a Director of Biology at the Tri-Institutional Therapeutics Discovery Institute.
Previously, Leigh was a staff scientist working on Inflammatory Bowel Disease at the Broad Institute in Boston. Prior to that, she worked at a small startup in Boston called Coronado Biosciences.
Leigh received her bachelor’s degree in Biology from Brown University in 2003 and a PhD from Stanford University School of Medicine in Microbiology and Immunology in 2009. She completed her postdoctoral training at Harvard University Medical School from 2010-2014.